FDA Warns of Risk of Using Keytruda


The FDA is reminding both patients and doctors that the cancer drug Keytruda (pembrolizumab) is not approved for use in multiple myeloma after an unusual number of deaths in clinical trials investigating Keytruda in combination with 2 other therapies for the blood cancer.

Two trials examining Keytruda in combination with immunomodulators such as Revlimid (lenalidomide) and Pomalyst (pomalidomide) for multiple myeloma were put on hold in July after investigators reported an “excess” number of deaths in those being treated with Keytruda compared to those in a control arm that did not include the drug. At that time, researchers stopped giving Keytruda to patients in the trials.

“Today’s alert underscores the importance of why new therapies are thoroughly studied to ensure the benefits of taking them outweigh the risks to patients, and we will continue to aggressively monitor clinical trials to ensure patients are protected when safety concerns arise,” Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

The FDA also said that if patients are taking Keytruda for approved uses — which include head and neck cancer, Hodgkin lymphoma and melanoma — they should continue taking the medication, as the agency believes the benefits outweigh the risks for these conditions.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x